News Releases
The following news releases are issued by GlaxoSmithKline Inc. In addition to these resources, you may also find GlaxoSmithKline global news of interest.
December 11, 2007
Global GSK Corporate Statement: GlaxoSmithKline Responds to the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes
November 26, 2007
Canadian AIDS Society and GlaxoSmithKline Inc. Invite MPs to Help Launch Canadian HIV/AIDS Awareness Week at Red Ribbon Event
November 14, 2007
Over 40% of critical healthcare workers may not go to work when a pandemic hits - Proper planning and preventive medicines are critical to ensure essential frontline healthcare services function during a pandemic
November 06, 2007
Added relief for patients with seasonal allergies: AvamysT now available in Canada
November 06, 2007
New guidance issued for diabetes drug Avandia
September 13, 2007
GlaxoSmithKline showcases $199 million expansion to Quebec City site
September 12, 2007
Global GSK Corporate Statement: GlaxoSmithKline Responds to JAMA Articles
August 08, 2007
GSK gives consent under Canada's Access to Medicines Regime for generic version of HIV/AIDS medicine for use in Rwanda
August 03, 2007
First North American clinical trials with GSK's candidate pre-pandemic vaccine to start
July 31, 2007
New Studies Show Valtrex® Reduces HSV-2 Outbreaks and viral Shedding among Patients Newly Diagnosed with Genital Herpes
July 31, 2007
FDA Advisory Panel Votes 22 to 1 For Avandia® to Remain Available to Patients in the US
June 27, 2007
Largest Cervical Cancer Vaccine Efficacy Trial Shows CervarixTM Provides Excellent Protection Against Lesions Caused by the Most Common Cancer-Causing Virus Types
June 11, 2007
GlaxoSmithKline Laval Facility Becomes North America Vaccine Research and Development Headquarters -- $50 million investment to support new role
June 05, 2007
CervarixTM, the GSK cervical cancer candidate vaccine, provides sustained immune response in 100 per cent of women up to 55 years of age
May 30, 2007
Global GSK Corporate Statement: Data affirms Avandia® (Rosiglitazone maleate) cardiovascular safety profile
May 21, 2007
Global GSK Corporate Statement: GlaxoSmithKline Responds to NEJM Article on Avandia®
April 17, 2007
CervarixTM, GSK's cervical cancer candidate vaccine, demonstrates 100 per cent protection against precancerous lesions caused by cancer-causing Human Papillomavirus Types 16 and 18 for more than five years
March 22, 2007
GSK Announces Approval of Arixtra® (fondaparinux sodium) for the Treatment of Angia and Heart Attacks -- Approvals based on Canadian-led, international trials of acute coronary
syndromes
March 05, 2007
New studies indicate GSK's pre-pandemic influenza vaccine can protect against different strains of H5N1
February 22, 2007
Results from landmark study suggest that Advair® provides important benefits for patients with COPD -- New England Journal of Medicine today publishes results of largest ever COPD study and the first to investigate the effect of treatment on the risk of death from this progressive, life-threatening lung disease
February 20, 2007
GlaxoSmithKline applauds landmark announcement in HIV/AIDS research -- Public-private partnership a step forward in Canada's vaccines research capability
February 09, 2007
GlaxoSmithKline commends $1.5 billion advance market commitment for pneumococcal vaccines
January 04, 2007
GlaxoSmithKline receives approval in Canada for use of Relenza® in prevention of Influenza
January 02, 2007
GlaxoSmithKline recognized as one of the 50 Best Employers in Canada -- Top Ten ranking for research-based pharmaceutical company.
